IMMUNEX- MINUS-60%-NACHBÖRSLICH - 500 Beiträge pro Seite

[germane]

Da ist eine Testreihe in die Buchse gegangen
ZU LESEN IMNX YAHOO FINANZEN USA

[germane]

9$ nur noch,man,man,man das ist hart

[Dotcomer]

Kann es sein, daß dies nicht das erste Medikament ist, bei welchem die Tests abgebrochen werden?

[Immanuel_K]

Ich kann dich beruhigen , dotcomer:

die allermeisten Testsubstanzen erreichen nie den Markt und nicht einmal frühere Testphasen.

Unglaubliche Branche, die Biotechs, was?

[Immanuel_K]

... stellen wir doch direkt den ganzen Bericht rein:

Thursday March 22, 5:57 pm Eastern Time
Immunex halting Enbrel tests for chronic heart failure

NEW YORK, March 22 (Reuters) - Drug maker Immunex Corp. (NasdaqNM:IMNX - news) said on Thursday said it will not proceed with testing of its arthritis drug Enbrel for treatment of chronic heart failure because the drug did not prove effective enough in clinical trials.

Seattle-based Immunex said it made the decision to stop Phase 2 and Phase 3 tests for Enbrel for treatment of chronic heart failure after guidance from an independent data monitoring board indicated the drug ``would not be able to meet efficacy end-points.``

``Future development decisions for Enbrel in chronic heart failure will be made after we have complete analysis of all data from these studies,`` said Leslie Garrison, Immunex senior vice president of clinical development.

Wall Street investors were banking on Immunex receiving the heart indication for Enbrel. Enbrel had sales of $194.1 million in the fourth quarter. Demand for Enbrel among arthritis patients has been so high that the company`s production capacity could not keep up, forcing the company to build new plants that are expected to come on line next year.

Both chronic heart failure patients and arthritis patients often have too much of the protein ``TNF`` in the system. It was believed that Enbrel could treat other diseases associated with inflammation, such as chronic heart failure, a potentially fatal disease that often afflicts patients who have had heart surgery.

In addition to the Enbrel news, Immunex said two Phase II trials of its experimental Nuvance drug showed no apparent benefit to asthma patients in opening up lung airways. The company is completing a third Phase II trial.

Immunex`s stock was slammed in after-hours trade, trading at $9-13/16 after closing at $18-7/8 on the Nasdaq.

Separately, Immunex and Wyeth-Ayerst Laboratories, a division of American Home Products Corp. (NYSE:AHP - news), also said psoriatic arthritis patients receiving Enbrel experienced significant improvement in signs and symptoms of their disease. AHP owns about a 40 percent stake in Immunex.

Psoriatic arthritis is a disease characterized by inflammatory arthritis and psoriasis, or skin patches and blotches that can cover a large portion of the body, an Immunex spokeswoman said.

Based on these results, the company plans to file a supplemental application with the U.S. Food and Drug Administration in mid-2001.

[TradeMaster9009]

****************************************************************************************

ICH WARNE IMMER NOCH VOR DEN BIOTECHS ... DER GROSSE (!) DOWNMOVE KOMMT ERST NOCH

****************************************************************************************

Ihr müsst selber wissen, was ihr tut, jedoch alle die meine Threads kennen, kennen meine KURSZIELE bis 2002 ... diese KURSZIELE werden erreicht - im BIOTECH-Sektor als auch im B2B-Sektor

DER MASTER

[revers]

interesiert sich ueberhaupt einer fuer deine kursziele mir langen die schon von den fachleuten also scweig lieber